Carbonic anhydrase inhibitors and DEXi show superior CMT reduction in retinitis pigmentosa macular oedema
New Analysis Compares Treatments for Retinitis Pigmentosa Macular Oedema
This network meta-analysis evaluates various treatments for retinitis pigmentosa (RP)-associated macular oedema. The study found that carbon…
Different medications show varying success in reducing swelling and improving vision for patients with retinitis pigmentosa-associated macul…
Anti-VEGF plus corticosteroids improves BCVA and reduces edema recurrence in BRVO and CRVO
Combination therapy improves vision for patients with retinal vein occlusion
This meta-analysis of 2040 patients found that anti-VEGF plus corticosteroid combination therapy resulted in better BCVA (MD -0.09) and redu…
Adding corticosteroids to anti-VEGF injections can improve vision and reduce the need for frequent eye injections in certain retinal conditi…
101-PGC-005 achieves HR 2.31 for faster WHO scale improvement over dexamethasone in COVID-19
New drug beats dexamethasone for moderate COVID-19 recovery
This randomized Phase II/III trial of 309 hospitalized patients with moderate COVID-19 found that 101-PGC-005 (20 mg IV daily for 3 days) si…
A new drug helped hospitalized COVID-19 patients recover a day faster than dexamethasone, with similar safety.
Network meta-analysis compares adjunctive therapies for proliferative vitreoretinopathy
Oral retinoic acid shows promise for retinal detachment repair
Oral retinoic acid significantly improves retinal reattachment rates in PVR patients, with strong evidence for visual acuity and reduced com…
A study found oral retinoic acid may improve retinal reattachment rates after surgery for certain eye conditions, offering a potential new t…
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery
Combining two drugs offered no pain relief advantage over one drug alone
This randomized, triple-blind trial in 100 patients undergoing upper limb surgery found that adding i.v.
A trial of 100 patients found that adding dexmedetomidine to dexamethasone did not extend pain relief or reduce opioid use after upper limb …
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial
High Inflammation Might Reduce Placebo Effect in Cancer
This exploratory analysis of an RCT in 45 cancer patients with dyspnea found a negative association between baseline cytokine levels and sym…
Scientists found that high inflammation levels may stop the placebo effect from working well.
EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN Pilot
Early Meds Could Cut Hospital Stays for Wheezing Kids
This Phase 2 pilot trial in the Pediatric Emergency Care Applied Research Network assessed an EMS treatment bundle and checklist for childre…
Kids with severe asthma might avoid hospital stays if they get breathing meds right after the 911 call.